Market Overview

Maxim Explains Why Gilead Sciences Is A Now A Buy

Maxim Explains Why Gilead Sciences Is A Now A Buy
Related GILD
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares
Stocks To Watch: FANGs Out In Tech (Seeking Alpha)

Gilead Sciences, Inc. (NASDAQ: GILD) stands to benefit on multiple fronts, which prompted an analyst to upgrade the shares of the company Thursday.

The Analyst

Maxim Group analyst Jason McCarthy upgraded his rating on the shares of Gilead Sciences from Hold to Buy and  set a $94 price target. 

The Thesis

The Kite Pharma Inc (NASDAQ: KITE) buy comes with the stock "for free"; the comparisons are easing for Gilead Sciences' HCV franchise; and Gilead had $2.7 billion in free cash flow in the recently reported quarter, McCarthy said in a note. (See McCarthy's track record here.) 

Following a meeting with senior executives in Beijing, where manufacturing plans for the launch of Yescarta were presented, Maxim said it is now confident the company can overcome manufacturing challenges to commercialize in the U.S. and globally.

Yescarta — a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment — was approved by the FDA in October. Maxim views this as the start, with approvals likely coming in Europe, China and Japan.

"With a global presence in late stage B cell cancer, Gilead is positioned to generate over $5 billion in outyears," McCarthy said. 

Maxim's model now incorporates Yescarta revenues from China and Japan, in addition to revenues from both the U.S. and EU. The Kite acquisition makes Gilead Sciences an industry leader in cell therapy, McCarthy said.

"This is the start of a new oncology paradigm." 

The Price Action

Gilead Sciences' shares are up 2.88 percentyear-to-date, underperforming the 17.3-percent gain for the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB).

At the time of writing, shares of Gilead Sciences were rising 1.33 percent to $74.65.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Amazon, Gilead, Nordstrom: Fast Money Picks For November 28

Latest Ratings for GILD

Jun 2018Raymond JamesInitiates Coverage OnStrong Buy
May 2018PiperJaffrayAssumesOverweightOverweight
May 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Jason McCarthy Maxim GroupAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (GILD + IBB)

View Comments and Join the Discussion!